Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Nuvalent (NUVL) Research & Development (2020 - 2026)

Nuvalent filings provide 7 years of Research & Development readings, the most recent being $83.6 million for Q1 2026.

  • Quarterly Research & Development rose 12.35% to $83.6 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $316.2 million through Mar 2026, up 24.69% year-over-year, with the annual reading at $307.0 million for FY2025, 40.96% up from the prior year.
  • Research & Development hit $83.6 million in Q1 2026 for Nuvalent, up from $67.8 million in the prior quarter.
  • Across five years, Research & Development topped out at $83.8 million in Q3 2025 and bottomed at $12.7 million in Q1 2022.
  • Average Research & Development over 5 years is $46.2 million, with a median of $38.6 million recorded in 2024.
  • The largest annual shift saw Research & Development skyrocketed 131.46% in 2022 before it fell 2.34% in 2025.
  • Nuvalent's Research & Development stood at $22.9 million in 2022, then surged by 55.7% to $35.6 million in 2023, then skyrocketed by 95.09% to $69.4 million in 2024, then decreased by 2.34% to $67.8 million in 2025, then increased by 23.32% to $83.6 million in 2026.
  • Per Business Quant, the three most recent readings for NUVL's Research & Development are $83.6 million (Q1 2026), $67.8 million (Q4 2025), and $83.8 million (Q3 2025).